Ono Pharmaceutical Co., Ltd.

Vanderbilt University

Haruto Kurata

Hiromu Habashita

Shinji Nakade

Kensuke Kusumi

Takeji Ono

Craig William Lindsley

Takahiro Mori

Kentaro Yashiro

Hiroshi Hagiya

Takaki Komiya

Masashi Minami

Yuzo Iwaki

Kevin M McGowan

Hirotaka Mizuno

Hiroshi Saga

Joshua M Wieting

Kazuhiro Ohtsuki

Yoko Sekioka

Jerod S Denton

Atsushi Naganawa

Joseph Raker

Mark Allan Wolf

Yuichi Inagaki

Yasuyo Kodera

Hiroya Takizawa

Activator of TREK (TWIK RElated Kchannels) channels

A compound represented by general formula (I) wherein all the symbols are as defined in the specification has a selective S1P5 receptor agonist activity due to having a linker from a phenyl group to a cyclic substituent in a dihydronaphthalene skeleton; i.e., due to having a short linker of one atom or less as L in general formula (I), and can therefore serve as an agent for treating S1P5-mediated disease, e. g., neurodegenerative disease such as schizophrenia. 

Dihydronaphthalene derivative

A compound having an ability to bind to an SIP receptor and represented by formula (I), a salt thereof, a solvate thereof or a prodrug thereof is useful for prevention and/or treatment of rejection of transplantation, graft-versus-host disease, autoimmune disease, allergic disease and the like: 

Compound capable of binding S1P receptor and pharmaceutical use thereof

The present invention relates to a compound represented by the formula (I), a salt thereof, an N-oxide form thereof, a solvate thereof, or a prodrug thereof, and a medicament containing the same. The compound represented by the formula (I) has an ability to bind to an S1P receptor (particularly, EDG-1, EDG-6, and/or EDG-8) and is useful for preventing and/or treating for rejection to transplantation, graft-versus-host disease, autoimmune diseases, allergic diseases, neurodegenerating diseases, and the like. 

Aminocarboxylic acid derivative and medicinal use thereof

A compound having an ability to bind to an S1P receptor (particularly EDG-6, preferably EDG-1 and EDG-6), for example, the compound represented by formula (I) of the present invention, a salt thereof, a solvate thereof or a prodrug thereof is useful for prevention and/or treatment of rejection of transplantation, graft-versus-host disease, autoimmune disease, allergic disease and the like. wherein ring A is a cyclic group; ring B is a cyclic group which may have substituent(s); X is a spacer having 1 to 8 atoms in its main chain, etc.; Y is a spacer having 1 to 10 atoms in its main chain, etc.; n is 0 or 1, wherein when n is 0, m is 1 and Ris a hydrogen atom or a substituent, and wherein when n is 1, m is 0 or an integer of 1 to 7 and Ris a substituent, and wherein m is 2 or more, Rs are the same or different.

It is intended to provide compounds having EDG-5 antagonism. Because of having EDG-5 antagonism, compounds of the formula (I): wherein each symbol is as defined in the description; salts thereof, N-oxides thereof, solvates thereof or prodrugs thereof are useful as preventive and/or therapeutic agent for EDG-5 mediated diseases, for example, diseases caused by blood vessel contraction (e.g. cerebrovascular spasms disease, cardiovascular spasms diseases, coronary artery spasms disease, hypertension, pulmonary hypertension, renal diseases, myocardial infarction, angina pectoris, arrhythmia, portal hypertension, varicosity and the like), arteriosclerosis, pulmonary fibrosis, hepatic fibrosis, renal fibrosis, respiratory diseases (e.g. bronchial asthma, chronic obstructive pulmonary diseases and the like), nephropathy, diabetes, hyperlipemia and the like.

Azetidine ring compounds and drugs comprising the same

Growing community of inventors

Mishima-gun, Japan

Haruto Kurata